PMN ProMIS Neurosciences: Multiplikator Forward P/S

The development of therapies for neurodegenerative pathologies is independent of macroeconomics, rendering the business non-cyclical for ProMIS Neurosciences (PMN). The expected P/S multiple visualizes these characteristics, with recorded as the baseline value. However, a high burn rate and competition in Alzheimer's treatment create financial instability. These risks are mitigated through long-term contracts with CDMO vendors, which guarantee the quality of the produced antibodies.

To assess the resilience of ProMIS Neurosciences (PMN) amid a fierce battle with pharma behemoths for the Alzheimer's therapy market, monitoring the expected business value is critical. By analyzing the forward price-to-sales valuation trend, an investor can compare market capitalization with projected revenues, making it possible to identify cooling interest in the asset or the risk of a prolonged correction against the backdrop of competitors' successes.